Meeting
2014 ASCO Annual Meeting
Phase Ib trial of trastuzumab emtansine (TE) in combination with lapatinib (L) plus nab-paclitaxel in metastatic HER2-neu overexpressed breast cancer patients: STELA trial.
Authors
Tejal Amar Patel
Houston Methodist Cancer Center, Houston, TX
Tejal Amar Patel , Jaime Alberto Mejia , Angel Augusto Rodriguez , Jenny Chee Ning Chang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
Pending
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS669)
DOI
10.1200/jco.2014.32.15_suppl.tps669
Abstract #
TPS669
Poster Bd #
124B
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase ib study of trastuzumab emtansine (TDM1) in combination with lapatinib and nab-paclitaxel in metastatic HER2-neu overexpressed breast cancer patients: Stela results.
First Author: Tejal Amar Patel
Poster
2014 ASCO Annual Meeting
Phase I study of BYL719 and trastuzumab-MCC-DM1 (T-DM1) in HER2-positive metastatic breast cancer (MBC) patients with progression on trastuzumab and taxane-based therapy.
First Author: Sarika Jain
Poster
2018 ASCO Annual Meeting
Care 001: Multicenter randomized open label phase II trial of neoadjuvant trastuzumabemtansine (T-DM1) in combination with lapatinib and nab-paclitaxel compared with paclitaxel, trastuzumab and pertuzumab in HER 2 neu over-expressed breast cancer patients (TEAL study).
First Author: Tejal Amar Patel
Poster
2011 ASCO Annual Meeting
Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I study in patients with metastatic HER2-amplified breast cancer.
First Author: D. Gajria